IGF-1R inhibition potentiates cytotoxic effects of chemotherapeutic agents in early stages of chemoresistant ovarian cancer cells.

The kinetics and effect of hyper activated IGF-1R signaling is not well investigated during acquirement of platinum and taxol resistance in ovarian cancer cells. Herein we reported an upregulated IGF-1R expression in early stages of cisplatin paclitaxel and cisplatin-taxol resistance. Picropodophyllin, an IGF-1R inhibitor, alone and in combination with cisplatin, paclitaxel or both at lowest possible doses could reverse the resistance at early stages. Upregulated IGF-1R was also found in primary tumors of ovarian cancer patients after three to four cycles of platinum-taxol treatment. These findings indicate that a combination of cytotoxic agents and IGF-1R inhibitor is more effective at early stages of chemoresistant ovarian cancer.
AuthorsRam K Singh, Snehal M Gaikwad, Ankit Jinager, Smrita Chaudhury, Amita Maheshwari, Pritha Ray
JournalCancer letters (Cancer Lett) Vol. 354 Issue 2 Pg. 254-62 (Nov 28 2014) ISSN: 1872-7980 [Electronic] Ireland
PMID25157649 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2014 Elsevier Ireland Ltd. All rights reserved.
Chemical References
  • picropodophyllin
  • Receptor, IGF Type 1
  • Proteasome Endopeptidase Complex
  • Podophyllotoxin
  • Paclitaxel
  • Cisplatin
  • Antineoplastic Combined Chemotherapy Protocols (pharmacology)
  • Cell Line, Tumor
  • Cisplatin (administration & dosage, pharmacology)
  • Down-Regulation
  • Drug Resistance, Neoplasm
  • Drug Synergism
  • Female
  • Humans
  • Molecular Targeted Therapy
  • Neoplasm Staging
  • Neoplasms, Glandular and Epithelial (drug therapy, metabolism, pathology)
  • Ovarian Neoplasms (drug therapy, metabolism, pathology)
  • Paclitaxel (administration & dosage, pharmacology)
  • Podophyllotoxin (administration & dosage, analogs & derivatives, pharmacology)
  • Proteasome Endopeptidase Complex (metabolism)
  • Receptor, IGF Type 1 (antagonists & inhibitors, biosynthesis)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: